Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients

Current Opinion in Organ Transplantation

Volumn 18, Issue 4, 2013, Pages 408-415

  Geissler, Edward K ^a   Hutchinson, James A ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

cell therapy; Mreg; The One Study; Tol DC; Tr1; Treg

Indexed keywords

ALLOGRAFT; CELL THERAPY; CELL TYPE; CHRONIC GRAFT REJECTION; GRAFT RECIPIENT; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LONG TERM EXPOSURE; ORGAN TRANSPLANTATION; REVIEW; RISK FACTOR;

GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; TISSUE THERAPY; TRANSPLANTATION TOLERANCE;

EID: 84880921389     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328363319d     Document Type: Review

References (62)

1. Kilshaw PJ, Brent L, Pinto M. An active suppressor mechanism preventing skin allograft rejection in mice. Transplant Proc 1975; 7:225-228
2. Hall BM, Jelbart ME, Dorsch SE. Suppressor T cells in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Transplantation 1984; 37:595-600
3. Hutchinson IV. Suppressor T cells in allogeneic models. Transplantation 1986; 41:547-555
4. Hall BM, Pearce NW, Gurley KE, et al. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J Exp Med 1990; 171:141-157
5. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-1164
6. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-1061
7. Ohkura N, Hamaguchi M, Morikawa H, et al. T cell receptor stimulationinduced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 2012; 37:785-799
8. Gregori S, Bacchetta R, Passerini L, et al. Isolation, expansion, and characterization of human natural and adaptive regulatory T cells. Methods Mol Biol 2007; 380:83-105
9. Hutchinson JA, Riquelme P, Sawitzki B, et al. Cutting edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol 2011; 187:2072-2078
10. Riquelme P, Geissler EK, Hutchinson JA. Alternative approaches to myeloid suppressor cell therapy in transplantation: Comparing regulatory macrophages to tolerogenic DCs and MDSCs. Transplant Res 2012; 1:17
11. Moreau A, Varey E, Bouchet-Delbos L, et al. Cell therapy using tolerogenic dendritic cells in transplantation. Transplant Res 2012; 1:13
12. Stoop JN, Robinson JH, Hilkens CM. Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: What can we learn from mouse models? Ann Rheum Dis 2011; 70:1526-1533
13. van Kooten C, Lombardi G, Gelderman KA, et al. Dendritic cells as a tool to induce transplantation tolerance: Obstacles and opportunities. Transplantation 2011; 91:2-7
14. Peng Y, Ke M, Xu L, et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: A clinical pilot study. Transplantation 2013; 95:161-168
15. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: A randomized controlled trial. JAMA 2012; 307:1169-1177
16. Sagoo P, Ali N, Garg G, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med 2011; 3:83ra42
17. Tang Q, Bluestone JA, Kang SM. CD4+Foxp3+ regulatory T cell therapy in transplantation. J Mol Cell Biol 2012; 4:11-21
18. Riquelme P, Tomiuk S, Kammler A, et al. IFN-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther 2012; in press
19. Macedo C, Turnquist HR, Metes D, et al. Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. Transplant Res 2012; 1:16
20. Hill M, Thebault P, Segovia M, et al. Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through IFN-g and EBI3. Am J Transplant 2011; in press
21. Inoue S, Popp FC, Koehl GE, et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006; 81:1589-1595
22. Schliesser U, Streitz M, Sawitzki B. Tregs: Application for solid-organ transplantation. Curr Opin Organ Transplant 2012; 17:34-41
23. Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: Strategies and first clinical experiences. Curr Opin Immunol 2011; 23:679-684
24. Hoffmann P, Eder R, Kunz-Schughart LA, et al. Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells. Blood 2004; 104:895-903
25. Ziegler SF. FOXP3: Of mice and men. Annu Rev Immunol 2006; 24:209-226
26. Di IM, Del PB, Cecchini D, et al. Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications. Clin Exp Immunol 2009; 156:246-253
27. Hoffmann P, Boeld TJ, Eder R, et al. Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant 2006; 12:267-274
28. Peters JH, Preijers FW, Woestenenk R, et al. Clinical grade Treg: GMP isolation, improvement of purity by CD127 depletion, Treg expansion, and Treg cryopreservation. PLoS One 2008; 3:e3161
29. Issa F, Hester J, Goto R, et al. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 2010; 90:1321-1327
30. Putnam AL, Brusko TM, Lee MR, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009; 58:652-662
31. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo expanded human regulatory T cells. Nat Med 2010; 16:809-813
32. Grutzkau A, Radbruch A. Small but mighty: How the MACS-technology based on nanosized superparamagnetic particles has helped to analyze the immune system within the last 20 years. Cytometry A 2010; 77:643-647
33. Hoffmann P, Eder R, Edinger M. Polyclonal expansion of human CD4+CD25+ regulatory T cells. Methods Mol Biol 2011; 677:15-30
34. Hoffmann P, Boeld TJ, Eder R, et al. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 2009; 39:1088-1097
35. Tresoldi E, Dell'Albani I, Stabilini A, et al. Stability of human rapamycinexpanded CD4+CD25+ T regulatory cells. Haematologica 2011; 96:1357-1365
36. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105:4743-4748
37. Hoffmann P, Eder R, Boeld TJ, et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006; 108:4260-4267
38. Masteller EL, Tang Q, Bluestone JA. Antigen-specific regulatory T cells-ex vivo expansion and therapeutic potential. Semin Immunol 2006; 18:103-110
39. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212:28-50
40. Roncarolo MG, Gregori S, Lucarelli B, et al. Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunol Rev 2011; 241:145-163
41. Davies JK, Barbon CM, Voskertchian A, et al. Ex vivo alloanergization with belatacept: A strategy to selectively modulate alloresponses after transplantation. Cell Transplant 2012; Epub ahead of print
42. Davies JK. Costimulatory blockade with monoclonal antibodies to induce alloanergy in donor lymphocytes. Int J Hematol 2011; 93:594-601
43. Davies JK, Gribben JG, Brennan LL, et al. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: Results of 2 phase 1 studies. Blood 2008; 112:2232-2241
44. Davies JK, Barbon CM, Voskertchian AR, et al. Induction of alloantigenspecific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade. J Vis Exp 2011; 49
45. Lutz MB. Therapeutic potential of semi-mature dendritic cells for tolerance induction. Front Immunol 2012; 3:123
46. Amodo G, Gregori S. Human tolerogenic DC-10: Perspectives for clinical applications. Transplant Res 2012; 1:14
47. Greifenberg V, Ribechini E, Rossner S, et al. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur J Immunol 2009; 39:2865-2876
48. Obermajer N, Kalinski P. Generation of myeloid-derived suppressor cells using prostaglandin E2. Transplant Res 2012; 1:15
49. Van RN, Le MA. Myeloid-derived suppressor cells: Characterization and expansion in models of endotoxemia and transplantation. Methods Mol Biol 2011; 677:169-180
50. Lutz MB. Buy one, get one free: Additional functions of GM-CSF in DC maturation. Eur J Immunol 2012; 42:35-38
51. Giannoukakis N, Phillips B, Finegold D, et al. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34:2026-2032
52. Eggenhofer E, Hoogduijn M. Mesenchymal stem cell-educated macrophages. Transplant Res 2012; 1:12
53. Hutchinson JA, Riquelme P, Geissler EK. Human regulatory macrophages as a cell-based medicinal product. Curr Opin Organ Transplant 2012; 17:48-54
54. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptanceinducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008; 21:728-741
55. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008; 21:742-754
56. Hutchinson JA, Govert F, Riquelme P, et al. Administration of donor-derived transplant acceptance-inducing cells to the recipients of renal transplants from deceased donors is technically feasible. Clin Transplant 2009; 23:140-145
57. Hutchinson JA, Roelen D, Riquelme P, et al. Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells. Transpl Int 2008; 21:808-813
58. Hutchinson JA, Riquelme P, Geissler EK, et al. Human regulatory macrophages. Methods Mol Biol 2011; 677:181-192
59. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120:1848-1861
60. Gilliss BM, Looney MR, Gropper MA. Reducing noninfectious risks of blood transfusion. Anesthesiology 2011; 115:635-649
61. Sanchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 2011; 140:51-64
62. Geissler EK. The ONE study compares cell therapy products in organ transplantation: Introduction to a review series on suppressive monocytederived cells. Transplant Res 2012; 1:11